

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: GARRILL, Karl Andrew, et. al.

rial No.: 09/971,799

Art Unit: 3728

"Filing Date: October 3, 2001

Examiner: Jimmy G. Foster

For: METHOD AND PACKAGE FOR STORING A PRESSURIZED CONTAINER CONTAINING A DRUG

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X] []	Copies of the references #10-24 are enclosed (#10-23 on enclosed CD-ROM; #24 paper copy) Copies of the references were submitted in parent application Serial No
A.	[]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	[X]	
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[X]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

06/23/2004 MBLANCO 00000002 071392 09971799

01 FC:1806 180.00 DA

OCT 29 2004

Atty. Docket No. PG4113US2

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.
	In accor	rdance with the requirements of 37 CFR 1.97(d):
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
[]		charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.
		D

Respectfully Sulfmitted

Attorney of Record: J. Michael Strickland

Registration No. 47,115

Date: June 21, 2004

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9024 Facsimile: (919) 483-7988 **FORM PTO-1449** ATTORNEY DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE STATEMENT PG4113US2 09/971,799 APPLICANT GARRILL, Karl Andrew, et. al. **FILING DATE** GROUP October 3, 2001 3728 U.S. PATENT DOCUMENTS Filing Date Examiner Patent **Issue Date** Name Class Subclass Appropriate Initials Number 05/08/1984 4,447,565 LULA, et. al. ١. 07/19/1988 4,757,919 SMAZIK, et. al. 2. 04/24/1990 MARUHASHI, et. al. 3. 4,919,984 11/05/1991 HEKAL 4. 5,062,569 5,591,379 01/07/1997 **SHORES** 5. 08/04/1998 RAM, et. al. 6. 5,789,044 12/11/2001 LIGONY 7. 6,328,327 01/20/2004 GARRILL, et. al. 8. 6,679,374 4,042,170 A 08/1977 ELKMAN, et. al. 9. Continue on page FOREIGN PATENT DOCUMENTS Translation **Document** Publication Yes | No Number Country Class Subclass Date 10. 96/04189 02/15/1996 **PCT PCT** 11. 96/29603 09/26/1996 96/33108 10/24/1996 PCT 12. 97/32663 09/12/1997 PCT 13. 4013799 04/28/1990 GERMANY (Abstract) 14. 2099940 01/07/1994 CANADA (Abstract) 15. 16. 2306169 04/30/1997 GREAT BRITAIN (Abstract) GERMANY (Abstract) 17. 19633495 02/26/2998 9947195 09/23/1999 PCT 18. 06/29/2000 19. 0037336 PCT 99/53901 10/1999 PCT 20. 1964048 A 5/1998 **GERMANY** 21. 12/1995 **EUROPE** 22 0688666 A 0793992 A 9/1997 **EUROPE** 23. Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) 24. Research Disclosure document RD 433072-A, entitled "Medical Device Package with Clear Plastic Overwrap;" 05/10/2000 Serial No.: 09/599,274 filed 06/22/2000 25. 26. Serial No.: 10/312,073 filed 06/22/2001 Continue on page **EXAMINER** DATÉ CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.